- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Biologics have been revolutionary in the treatment of atopic dermatitis, with several other recently approved therapies showing promise as well, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Transcript
Can you speak on the current use of biologics in atopic dermatitis and any unmet needs that can be improved through these therapies?
These therapies have been really revolutionary. I finished my fellowship in 2000 so I've been doing this for 22 years or so. And until 2017, for the first 17 years of posttraining work in this field for me, there were really no new molecules approved for treating eczema.
Around 2000 was when the topical calcineurin inhibitors came out. So, since then, until 2017, there really wasn't anything that was fundamentally novel in the way it worked until dupilumab. Dupilumab is a biologic medication, which has been life altering for a good number of my patients.
So, you ask about unmet needs. Really, the biggest unmet need was the ability to effectively treat itch, since that's sort of the core symptom and the problem from which so many other challenges stem in these patients. And dupilumab is very effective at treating itch; it's been effective in decreasing the risk of skin infections, presumably because the skin barrier is in better shape and improved. It has been a really remarkable drug.
Since then, really just in the last few months, another biologic has been approved, an interleukin [IL]-13 blocker. Dupilumab is an IL-4 and IL-13 blocker. Some small molecules, some Janus kinase [JAK] inhibitors, have been approved, 2 different oral medications—not biologics, but systemic medications for atopic dermatitis, which also seem like they're going to raise the bar and really increase the ability for providers to offer good therapeutic options for patients with eczema.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
